Company Overview and News

 
dorsaVi secures $1.1M government grant to enhance manufacturing facilities

2017-10-18 proactiveinvestors.com.au
dorsaVi Ltd (ASX:DVL) has secured a Federal Government Advanced Manufacturing Growth Fund grant of $1.1 million to support enhancements to its current manufacturing facilities.

 
dorsaVi granted unique body orientation patent in China

2017-05-04 proactiveinvestors.com.au
dorsaVi (ASX:DVL) has been granted the first patent for its body orientation intellectual property in China.

 
dorsaVi bags $1M from oversubscribed placement

2017-01-20 proactiveinvestors.com.au
The company has developed innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications.

 
dorsaVi raising $8M to expand motion analysis solutions

2016-12-13 proactiveinvestors.com.au
In addition to the placement, the company is offering a share purchase plan to existing shareholders, capped at $1 million. dorsaVi has developed innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. The funds raised from the placement will be primarily used for: - the recruitment and signing of additional Organisational Health & Safety (OHS) agents in the U.

 
DorsaVi gets ready to raise

2016-12-11 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Tuesday 13th December 2016, or earlier if an announcement is made to the market.

 
dorsaVi launches movement analysis solution with Crown Resorts

2016-12-01 proactiveinvestors.com.au
myViSafe will be used by Crown across its businesses in both Melbourne and Perth. This large scale project will involve over 13,500 employees who will be regularly assessed based on the level of manual handling risk within their particular jobs. myViSafe is comprised of an application for use on a phone or tablet, four mini movement sensors and a desktop dashboard. The sensors can be worn on the back or shoulders to measure movement in real-time in the workplace.

 
Revised Securities Trading Policy

2016-05-10 asx.com.au

 
Appendix 4C - quarterly

2016-04-27 asx.com.au

 
Appendix 3B

2016-04-05 asx.com.au

 
CEO Investor Presentation

2016-03-07 asx.com.au

 
Half Year Results Announcement

2016-02-08 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...